Dr. Srinivasan is a senior scientist working for a reputed biotechnology company known for its cutting-edge research in pharmaceuticals. Dr. Srinivasan is heading a research team working on a new drug aimed at treating a rapidly spreading variant of a new viral infectious disease. The disease has been rapidly spreading across the world and the cases reported in the country are increasing. There is huge pressure on Dr. Srinivasan’s team to expedite the trials for the drug as there is significant market for it, and the company wants to get the first-mover advantage in the market. During a team meeting, some senior team members suggest some shortcut for expediting the clinical trials for the drug and for getting the requisite approvals. These include manipulating data to exclude some negative outcomes and selectively reporting positive results, foregoing the process of informed consent and using compounds already patented by a rival company, rather than developing one’s own component. Dr. Srinivasan is not comfortable taking such shortcuts, at the same time he realises meeting the targets is impossible without using these means.

How a topper answered the closest question

Toppers wrote this one in a test series: “Dr. A.K. Singh, a professor of medicine, is a prominent cardiologist. His personal financial investments include significant stock holdings in three publicly traded biotechnology firms. He is approached by one of these firms to be a lead investigator in a therapeutic trial of a novel agent for preventing tissue damage from myocardial infarction (MI). This will be a randomized double-blinded, placebo-controlled clinical trial (neither patient nor physician will know whether the drug under investigation or a placebo is being used in a given patient). Dr. Singh is quite familiar with the preliminary animal and cell biology work in the area and believes that there is an excellent chance that this new drug will result in a significant improvement in survival and reduce damage to the heart muscle. He even thinks this novel agent may reduce the risk of heart failure and irregular beats. Dr. Singh's group is one of the few cardiology groups fully prepared to carry out this investigation, which is why he was contacted. He cares for a large number of patients with MI and believes that he could enroll numerous patients efficiently. The drug will only be available to his patients if his group participates in the trial. The company is offering Rs. 25 lakh for each patient enrolled. As a lead investigator, he will become much better known and will likely experience an increase in referrals if the trial succeeds. 1. Is Dr. Singh's participation in this study appropriate? Justify your position. 2. Does Dr. Singh have a conflict of interest? If so, what is the nature of the conflict? How could it be mitigated. 3. How would the nature of the conflict of interest be different had he not already owned stock, but instead had been offered stock as a form of compensation for conducting the study?”

Toppers’ answers to other close questions

• Regulation and procedure of human clinical trials vary from nation to nation. Stem cell research, as an emerging biomedical field, requires approval for human trials and encounters multiple challenges. You are the head of a team of scientists who developed a new Tissue Engineering system, which appears to be a promising means of regenerating heart tissue. Trials of the system have already been conducted on animals and yielded good results. Millions of people suffering from critical heart diseases would benefit immensely if this medication is immediately made available to them. However, you need to conduct human clinical trials before it could be commercialised. It is also known that the stringent regulatory environment in the country will mean that human trials and final approval will take many years before it is made commercially available. On the other hand, regulation of clinical trials in many poor countries is weak and quick approval is possible. Many of your competitors also resort to human trials in these countries, often bribing the officials for getting quick approvals. Given this situation, answer the following questions: (a) Identify the ethical issues which arise during clinical trials. (b) Given the above situation, would you prefer to shift human trials to a third country where regulations are lax? Give reasons in support of your choice. (c) Suggest a framework of standard procedure to minimise ethical conflicts and speed-up the approval process of new medicines.5 answers
• Dr. A.K. Singh, a professor of medicine, is a prominent cardiologist. His personal financial investments include significant stock holdings in three publicly traded biotechnology firms. He is approached by one of these firms to be a lead investigator in a therapeutic trial of a novel agent for preventing tissue damage from myocardial infarction (MI). This will be a randomized double-blinded, placebo-controlled clinical trial (neither patient nor physician will know whether the drug under investigation or a placebo is being used in a given patient). Dr. Singh is quite familiar with the preliminary animal and cell biology work in the area and believes that there is an excellent chance that this new drug will result in a significant improvement in survival and reduce damage to the heart muscle. He even thinks this new agent may reduce the risk of heart failure and irregular beats. Dr. Singh's group is one of the few cardiology groups fully prepared to carry out this investigation, which is why he was contacted. He cares for a large number of patients with MI and believes that he could enroll numerous patients efficiently. The drug will only be available to his patients if his group participates in the trial. The company is offering Rs. 25 lakh for each patient enrolled. As a lead investigator, he will become much better known and will likely experience an increase in referrals if the trial succeeds. 1. Is Dr. Singh's participation in this study appropriate? Justify your position. 2. Does Dr. Singh have a conflict of interest? If so, what is the nature of the conflict? How could it be mitigated. 3. How would the nature of the conflict of interest be different had he not already owned stock, but instead had been offered stock as a form of compensation for conducting the study?1 answer
• Dr. Mehra is a senior drug developer at a leading pharmaceutical company in India, renowned for producing various medications, including lifesaving drugs critical for treating chronic and rare diseases. Since its inception, the company has emphasized the quality and affordability of its drugs. Recently, under revised government guidelines, pharmaceutical companies are required to market a finished product only after obtaining "satisfactory results" from tests on the ingredients. Additionally, they must retain a sufficient quantity of samples of both intermediate and final products to allow repeated testing or verification of a batch. Dr. Mehra's team is in the final stages of developing a new medication for a rare but life-threatening disease. This drug has shown promising results in clinical trials. However, there have been unresolved concerns about the long-term side effects of the drug, observed in a small percentage of trial subjects. Despite this, the company has not released any major drug in the past decade, leading to significant pressure from the board members to expedite the drug's release. (a) Identify the stakeholders in the above case study. (b) Discuss the ethical issues faced by Dr. Mehra. (c) Analyse the options available to Dr. Mehra in the above case. Which of these would you choose and why?2 answers